Glaxosmithkline Plc Continues With Tender Offer To Acquire All Outstanding Shares Of Human Genome Sciences Inc

GlaxoSmithKline plc announced that it has received a renewed invitation from Human Genome Sciences Inc' to participate in its strategic alternatives review process which started in April. GSK also notes the newly announced date of July 16, 2012 for submission of definitive acquisition proposals. GSK's offer to acquire all of the outstanding shares of HGS for USD13.00 per share in cash represents a premium of 81% to HGS's closing share price of USD7.17 on April 18, 2012, the last trading day before HGS publicly disclosed GSK's private offer. In the meantime, GSK will continue to progress with its tender offer direct to HGS shareholders. The tender offer and withdrawal rights are scheduled to expire at New York City time on June 29, 2012. The closing of the tender offer is subject to the terms and conditions detailed in the offer document as filed on Schedule to with the U.S. Securities and Exchange Commission on May 10, 2012 and May 23, 2012.